Phosphodiesterase 4: Biological underpinnings for the design of improved inhibitors

Pharmacology Reviews and Communications

Volumn 8, Issue 1, 1996, Pages 65-73

  Barnette, Mary S ^a   Christensen, Siegfried B ^a   Underwood, David C ^a   Torphy, Theodore J ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Anti inflammatory; PDE4; Phosphodiesterase; Rolipram

Indexed keywords

EID: 2042433930     PISSN: 10288945     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Alvarez, R., Sette, C., Yang, D., Eglen, R. M., Wilhelm, R., Shelton, E. R. and Conn, M. (1995) Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. Molecular Pharmacology, 48, 616-622.
2. Badger, A. M., Oliver, D. L. and Esser, K. M. (1994) Beneficial effect of the phosphodiesterase inhibitors, BRL 61063, pentoxifylline, and rolipram in a murine model of endotoxin shock. Circulatory Shock, 44, 188-195.
3. Banner, K. H. and Page, C. P. (1995) Acute versus chronic administration of phosphodiesterase inhibitors on allergen-induced pulmonary cell influx in sensitized guinea-pigs. British Journal of Pharmacology, 114, 93-98.
4. Barnard, J. W., Seibert, A. F., Prasad, V. R., Smart, D. A., Strada, S. J., Taylor, A. E. and Thompson, W. J. (1994) Reversal of pulmonary capillary ischemia-reperfusion injury by rolipram, a cAMP phosphodiesterase inhibitor. Journal of Applied Physiology, 77, 774-781.
5. Barnette, M. S., Grous, M., Cieslinski, L. B., Burman, M., Christensen, S. B. and Torphy, T. J. (1995a) Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in isolated rabbit gastric glands: Correlation between function and interaction with a high affinity rolipram-binding site. Journal of Pharmacology and Experimental Therapeutics, 273, 1396-1402.
6. Barnette, M. S., Manning, C. D., Cieslinski, L. B., Burman, M., Christensen, S. B. and Torphy, T. J. (1995b) The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea-pig eosinophils is correlated with inhibition of PDE IV catalytic activity. Journal of Pharmacology and Experimental Therapeutics, 273, 674-679.
7. 3H]-rolipram binding. Biochemical Pharmacology, (in press).
8. Beavo, J. A., Conti, M. and Heaslip, R. J. (1994) Multiple cyclic nucleotide phosphodiesterases. Molecular Pharmacological, 46, 399-105.
9. Bolger, G. B. (1994) Molecular biology of the cyclic AMP-specific nucleotide phosphodiesterases: A diverse family of regulatory enzymes. Cellular Signalling, 6, 851-859.
10. Bolger, G., Michaeli, T., Martins, T., St. John, T., Steiner, B., Rodgers, L., Riggs, M., Wigler, M. and Ferguson, K. (1993) A family of human phosphodiesterases homologous to Dunce learning and memory gene of Drosophila melanogaster are potential targets for anti-depressant drugs. Molecular and Cellular Biology, 13, 6558-6571.
11. Bolger, G. B., Rodgers, L. and Riggs, M. (1994) Differential CNS expression of alternative mRNA isoforms of the mammalian genes encoding cAMP-specific phosphodiesterases. Gene, 149, 237-244.
12. Chan, S. C. and Hanifin, J. M. (1993) Differential inhibitor effects on cyclic adenosine monophosphate-phosphodiesterase isoforms in atopic and normal leukocytes. Journal of Laboratory and Clinical Medicine, 121, 44-51.
13. 2 regulation of cytokine production in atopic dermatitis. Journal of Immunology, 151, 3345-3352.
14. Christensen, S. B. and Torphy, T. J. (1994) Isozyme-selective phosphodiesterase inhibitors as antiasthmatic agents. Annual Reports in Medicinal Chemistry, 29, 185-194.
15. Conti, M., Jin, S.-L. C., Monaco, L., Repaske, D. R. and Swinnen, J. V. (1991) Hormonal regulation of cyclic nucleotide phosphodiesterases. Endocrine Reviews, 12, 218-234.
16. Eckmann, F., Fichte, K., Meya, U. and Sastre-Y-Hernandez, M. (1988) Rolipram in major depression: Results of a double-blind comparative study with amitriptyline. Current Therapeutic Research, 43, 291-295.
17. Engels, P., Sullivan, M., Muller, T. and Lubbert, H. (1995) Molecular cloning and functional expression in yeast of a human cAMP-specific phosphodiesterase subtype (PDE IV-C) FEBS Letters, 358, 305-310.
18. Engles, P., Fichtel, K. and Lubbert, H. (1994) Expression and regulation of human and rat phosphodiesterase type TV isogenes. FEBS Letters, 350, 291-295.
19. Fischer, W., Schudt, C. and Wendel, A. (1993) Protection by phosphodiesterase inhibitors against endotoxin-induced liver injury in galactosamine-sensitized mice. Biochemical Pharmacology, 45, 2399-2404.
20. Fleischhacker, W. W., Hinterhuber, H., Bauer, H., Pflug, B., Berner, P., Simhandl, C., Wolf, R., Gerlach, W., Jaklitsch, H., Sastre-Y-Hernandez, M., Schmeding-Wiegel, H., Sperner-Unterweger, B., Voet, B. and Schubert, H. (1992) A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder. Neuropsychobiology, 26, 59-64.
21. Genain, C P., Roberts, T., Davis, R. L., Nguyen, M.-H., Uccelli, A., Faulds, D., Li, Y., Hedgpeth, J. and Hauser, S. L. (1995) Prevention of autoimmune demyelinatin in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proceedings National Academy of Sciences, USA, 92, 3601-3605.
22. Griswold, D. E., Webb, E F., Breton, J., White, J. R., Marshall, P. J. and Torphy, T. J. (1993) Effect of selective phosphodiesterase type TV inhibitor, rolipram, on fluid and cellular phase of inflammatory response. Inflammation, 17, 333-344.
23. m cyclic AMP phosphodiesterase inhibition in tracheal relaxation and bronchodilation in the guinea pig. Journal of Pharmacology and Experimental Therapeutics, 251, 199-206.
24. Heaslip, R. J., Buckley, S. K., Sickels, B. D. and Grimes, D. (1991) Bronchial vs. cardiovascular activities of selective phosphodiesterase inhibitors in the anesthetized beta-blocked dog. Journal of Pharmacology and Experimental Therapeutics, 257, 741-747.
25. Horowski, R. and Sastre-Y-Hernandez, M. (1985) Clinical effects of the neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: Global evaluation of the preliminary reports. Current Therapeutic Research, 38, 23-29.
26. Howell, R. E., Sickels, B. D. and Woeppel, S. L. (1993) Pulmonary antiallergic and bronchodilator effects of isozyme-selective phosphodiesterase inhibitors in guinea pigs. Journal of Pharmacology and Experimental Therapeutics, 264, 609-615.
27. Jacobitz, S., McLaughlin, M. M., Livi, G. P , Burman, M. and Torphy, T. J. (1996) Mapping the functional domains of human recombinant phosphodiesterase 4A Structural requirements for catalytic activity and rolipram binding. Journal of Biological Chemistry, (in press).
28. Kato, H., Araki, T., Itoyama, Y. and Kogure, K. (1995) Rolipram, a cyclic AMP-selective phosphodiesterase inhibitor, reduces neuronal damage following cerebral ischemia in the gerbil. European Journal of Pharmacology, 272, 107-110.
29. Kaulen, P., Bruning, G., Schneider, H. H., Sarter, M. and Baumgarten, H. G. (1989) Autoradiographic mapping of a selective cyclic adenosine monophosphate phosphodiesterase in rat brain with the antidepressant [3H] rolipram. Brain Research, 503, 229-245.
30. Lagente, V., Moodley, I., Perrin, S., Mottin, G. and Jumien, J-L. (1994) Effects of isozyme-selective phosphodiesterase inhibitors on eosinophil infiltration in the guinea-pig lung. European Journal of Pharmacology, 255, 253-256.
31. Lagente, V., Pruniaux, M.-P., Junien, J.-L. and Moodley, I. (1995) Modulation of cytokine-induced eosinophil infiltration by phosphodiesterase inhibitors. American Journal of Respiratory and Critical Care Medicine, 151, 1720-1724.
32. B2) in brain: selective localization in membrane and cytosolic compartments and differential expression in various brain regions. Biochemical Journal, 304, 399-406.
33. Manganiello, V. C., Murata, T., Taira, M., Belfrage, P. and Degerman, E. (1995) PERSPECTIVES IN BIOCHEMISTRY AND BIOPHYSICS Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. Archives of Biochemistry and Biophysics, 322, 1-13.
34. Manning, C. D., McLaughlin, M. M., Livi, G. P., Cieslinski, L. B., Torphy, T. J. and Barnette, M. S. (1996) Prolonged b-adrenoceptor stimulation upregulates cAMP phosphodiesterase activity in human monocytes by increasing mRNA and protein for phosphodiesterases 4A and 4B. Journal of Pharmacology and Experimental Therapeutics, 276, 810-818.
35. m, rolipram-sensitive, cAMP-specific phosphodiesterase from human brain. Journal of Biological Chemistry, 268, 6470-6476.
36. Milatovich, A., Bolger, G., Michaeli, T. and Frandke, U. (1994) Chromosome localizations of genes for five cAMP-specific phosphodiesterases in man and mouse. Somatic Cell and Molecular Genetics, 20, 75-86.
37. Moodley, I., Sotsios, Y. and Bertin, B. (1995) Modulation of oxazolone-induced hypersensitivity in mice by selective PDE inhibitors. Mediators of Inflammation, 4, 112-116.
38. Newsholme, S. J. and Schwartz, L. (1993) cAMP-specific phosphodiesterase inhibitor, rolipram, reduces eosinophil infiltration evoked by leukotrienes or by histamine in guinea pig conjunctiva. Inflammation, 17, 25-31.
39. Obernolte, R., Bhakta, S., Alvarez, R., Bach, C., Zuppan, P., Mulkins, M., Jarnagin, K. and Shelton, E. R. (1993) The cDNA of a human lymphocyte cyclic-AMP phosphodiesterase (PDE IV) reveals a multigene family. Gene, 129, 239-247.
40. Oritz, J. L., Cortijo, J., Valles, J. M., Bou, J. and Morcillo, E. J. (1992) Rolipram inhibits PAF-induced airway microvascular leakage in guinea-pigs: A comparison with mulrinone and theophylline. Fundamental Clinical Pharmacology, 6, 247-249.
41. Prabhakar, U., Lipshutz, D., O'Leary Bartus, J., Slivjak, M. J., Smith, E. F. and Esser, K. (1994) Characterization of cAMP-dependent inhibition of LPS-induced TNFa production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. International Journal of Immunopharmacology, 16, 805-816.
42. Puurunen, J., Lucke, C. and Schwabe, U. (1978) Effect of the phosphodiesterase inhibitor 4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK 62711) on gastric secretion and gastric mucosal cyclic AMP. Naunyn-Schmiedeberg's Archives of Pharmacology, 304, 69-75.
43. Raeburn, D. and Karlsson, J.-A. (1993) Effects of isoenzyme-selective inhibitors of cyclic nucleotide phosphodiesterase on microvascular leak in guinea pig airways in vivo. Journal of Pharmacology and Experimental Therapeutics, 267, 1147-1152.
44. Raebum, D., Underwood, S. L., Lewis, S. A., Woodman, V. R., Battram, C. H., Tomkinson, A., Sharma, S., Jordan, R., Souness, J. E., Webber, S. E. and Karlsson, J.-A. (1994) Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor, British Journal of Pharmacology, 113, 1423-1431.
45. Santing, R. E., Olymulder, C. G., Van der Molen, K., Meurs, H. and Zaagsma, J. (1995) Phosphodiesterase inhibitors reduce bronchial hyperreactivity and airway inflammation in unrestrained guinea pigs. European Journal of Pharmacology, 275, 75-82.
46. Schmiechen, R., Schneider, H. H. and Watchel, H. (1990) Close correlation between behavioural response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase. Psychopharmacology, 102, 17-20.
47. Schneider, H. H., Schmiechen, R., Brezinski, M. and Seidler, J. (1986) Stereospecific binding of the antidepressant rolipram to brain protein structures. European Journal of Pharmacology, 127, 105-115.
48. Sekut, L., Yarnall, D., Stimpson, S. A., Noel, L. S., Bateman-Fite, R., Clark, R. L., Brackeen, M. F., Menius, J. A. and Connolly, K. M. (1995) Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation. Clinical Experimental Immunology, 100, 126-132.
49. Sette, C., Iona, S. and Conti, M. (1994a) The short-term activation of a rolipram-sensitive, cAMP-specific phosphodiesterase by thyroid-stimulating hormone in thyroid FRTL-5 cells is mediated by a cAMP-dependent phosphorylation. Journal of Biological Chemistry, 269, 9245-9252.
50. Sette, C., Vicini, E. and Conti, M. (1994b) The ratPDE3/IVd phosphodiesterase gene codes for multiple proteins differentially activated by cAMP-dependent protein kinase. Journal of Biological Chemistry, 269, 18271-18274.
51. Shakur, Y., Pryde, J. G. and Houslay, M. D. (1993) Engineered deletion of the unique N-terminal domain of the cyclic AMP-specific phosphodiesterase RD1 prevents plasma membrane association and the attainment of enhanced thermostability without altering its sensitivity to inhibition by rolipram. Biochemical Journal, 292, 677-686.
52. Sommer, N., Loschmann, P.-A. Northoff, G. H., Weller, M., Steinbrecher, A., Steinbach, J. P., Lichtenfels, R., Meyermann, R., Reithmuller, A., Fontana, A., Dichgans, J. and Martin, R. (1995) The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nature Medicine, 1, 244-248.
53. Souness, J. E. and Scott, L. C. (1993) Stereospecificity of rolipram actions on eosinophil cyclic AMP-specific phosphodiesterase. Biochemical Journal, 291, 389-395.
54. Svensjo, E., Andersson, K. E., Bouskela, E., Cyrino, F. Z. G. A. and Lindgren, S. (1993) Effects of two vasodilatory phosphodiesterase inhibitors on bradykinin-induced permeability increase in the hamster cheek pouch. Agents Actions, 39, 35-41.
55. Swinnen, J. V., Tsikalas, K. E. and Conti, M. (1991) Properties and hormonal regulation of two structurally related cAMP phosphodiesterases from the rat sertoli cell. Journal of Biological Chemistry, 266, 18370-18377.
56. Teixeira, M. M., Rossi, A. G., Williams, T. J. and Hellewell, P. G. (1994) Effects of phosphodiesterase isoenzyme inhibitors on cutaneous inflammation in the guinea-pig. British Journal of Pharmacology, 112, 332-340.
57. Torphy, T. J., DeWolf, W. E., Green, D. W. and Livi, G. P. (1993) Biochemical characteristics and cellular regulation of phosphodiesterase IV. Agents and Actions, 43S, 51-71.
58. Torphy, T. J. and Hall, I. P. (1994) Cyclic AMP and the control of airways smooth muscle tone. In Airways Smooth Muscle: Biochemical Control of Contraction and Relaxation (eds. D. Raeburn and M. A. Giembycz). Birkhauser Verlag, Basel, Switzerland, pp. 215-232.
59. Torphy, T. J., Murray, K. J. and Arch, J. R. S. (1994) Selective phosphodiesterase isozyme inhibitors. In Drugs and the Lung, (eds. C. P. Page and W. J. Metzger) Raven Press, Ltd., New York, pp. 397-447.
60. Torphy, T. J., Stadel, J. M., Burman, M., Cieslinski, L. B., McLaughlin, M. M., White, J. R. and Livi, G. P. (1992) Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast. Journal of Biological Chemistry, 267, 1798-1804.
61. Torphy, T. J. and Undem, B. J. (1991) Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax, 46, 512-523.
62. Torphy, T. J., Zhou, H.-L. and Cieslinski, L. B. (1992) Elevation of cyclic AMP content in U937 cells increases the activity of the cyclic AMP-specific phosphodiesterase. Journal of Pharmacology and Experimental Therapeutics, 263, 1195-1204.
63. 2. Journal of Biological Chemistry, 270, 23598-23604.
64. Turner, C. R., Andersen, C. J., Smith, W. B. and Watson, J. W. W. (1994) Effects of rolipram on responses to acute and chronic antigen exposure in monkeys. American Journal of Respiratory and Critical Care Medicine, 149, 1153-1159.
65. Underwood, D. C., Osborn, R. R., Kotzer, C. J., Bochnowicz, S., Luttman, M. A., Hay, D. W. P., Gorycki, P. D., Christensen, S. B. and Torphy, T. J. (1994) Profile of SB 207499, a selective inhibitor of phosphodiesterase (PDE) IV, in antigen-induced bronchoconstriction and eosinophil influx in the guinea pig. American Journal of Respiratory and Critical Care Medicine, 149, A762.
66. Underwood, D. C., Osborn, R. R., Novak, L. B., Matthews, J. K., Newsholme, S. J., Undem, B. J., Hand, J. M. and Torphy, T. J. (1993) Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the phosphodiesterase IV inhibitor, rolipram. Journal of Pharmacology and Experimental Therapeutics, 266, 306-313.
67. Verghese, M. W., McConnell, R. T., Lenhard, J. M., Hamacher, L. and Jin, S.-L., C. (1995a) Regulation of of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells. Molecular Pharmacology, 47, 1164-1171.
68. Verghese, M. W., McConnell, R. T., Strickland, A. B., Gooding, R. C., Sampson, S. A., Yarnall, D. P., Taylor, J. D. and Furdon, P. J. (1995b) Differential regulation of human monocyte-derived TNFα and IL-1β by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors. Journal of Pharmacology and Experimental Therapeutics, 272, 1313-1320.
69. Wachtel, H. (1983) Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′,5′-monophosphate phosphodiesterase inhibitors. Neuropharmacology, 22, 267-272.